- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Wanbury delivered a strong performance for FY26, signaling a successful business turnaround. Revenue grew 8% YoY to ₹650.27 Cr, while Profit After Tax (PAT) surged 117% YoY to ₹66.13 Cr. EBITDA rose 35% YoY to ₹107.69 Cr, with margins improving significantly to 16.6%. Basic EPS hit ₹20.55, up 120% YoY.
The API segment, accounting for 88% of revenue, grew 8% to ₹574 Cr. The Formulations business saw 7% growth to ₹76 Cr, achieving profitability break-even in FY26. Q4FY26 revenue saw a 4% YoY decline to ₹164.58 Cr, influenced by the West Asia crisis impacting API export dispatches.
Strategic focus includes expanding API presence in regulated markets and launching 4 new molecules annually from FY27. A new Anaesthetic API was commercialized in Q4FY26. Wanbury has also refinanced debt at a lower 12.5% interest rate, deleveraging significantly. Management looks forward to continued API growth and a stronger formulations business in FY27, backed by new launches and strategic market penetration.